semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Lung Cancer Age between 18 and 70 years of age, male or female 2. histologically or cytologically confirmed stage IIIB or IV lung cancer at diagnosis 3. no evidence of bone metastatic lesions was radiographically confirmed by bone scintigraphy 4. life expectancy of ≥6 months 5. adequate renal, hematologic, and hepatic 6. Eastern Cooperative Oncology Group(ECOG) performance status≤2 7. All patients provided written informed consent  Treatment with other bisphosphonates 2. Presence of brain metastases 3. Be allergic to ZOL 4. attending other unlisted drug clinical trials,currently
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Prostatic Neoplasms Patients with histologically proven prostate cancer. 2. Hormonal treatment (either surgical orchiectomy or medical castration with LHRH agonist or antagonist). 3. Proven castration levels (serum Testosterone< 50 ng/dl) 4. Radiological evidence of metastatic disease. 5. Uptake of the radiotracer 68Ga-DOTATET in at two least to metastases  Participation in another trial
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 14.0-19.0,  Orthodontic Anchorage Procedures Mild to moderate skeletal Class II Super eruption of maxillary posterior segment Erupted full set of maxillary permanent teeth except 3rd molar Increased lower facial height  Previous orthodontic treatment Any hormonal disorders or syndromes Systemic Disease Facial Asymmetry Para-functional habits
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Neoplasms, Connective and Soft Tissue Bone Neoplasms Must have a diagnosis or presumed diagnosis of bone or soft tissue tumor as defined by the WHO classification of tumors of soft tissue and bone (4th ed.) Patient, or his/her designated power of attorney, must be able to understand and approve of the consent to participate  Prisoners are excluded from participation in the Registry
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Endosseous Dental Implant Failure All patients in need for implant treatment  None
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-70.0,  Osteoarthritis Bilateral Total Knee Arthroplasty Age ≤ 70 years Undergoing bilateral, simultaneous, primary knee replacements  neurological, vascular or cardiac problems that limit function unstable orthopedic conditions that limit functional performance previous history of inflammatory arthritis or other inflammatory systemic conditions previous history of deep vein thrombosis in either lower extremity lymphedema or other conditions that lead to lower extremity edema that may influence the outcomes of the study
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  HPV Vaccination Born in Mexico or born in the U.S. but self-describes as Mexican-American Spanish is her/his primary language Has a minimum of one child between the ages of 9 and 17 who has not received the HPV vaccine and who lives with the parent/guardian as per self report Self-identifies as the child's main caregiver Currently owns a cell phone, uses text messaging services and is willing to accept text messages for this study  Will not be in the NYC area for the duration of the study period (6-9 months) Presence of a serious psychiatric or cognitive impairment likely to preclude meaningful informed consent and adherence to the protocol per the consenting professional's judgment
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Edentulous Alveolar Ridge Patients with bilateral edentulous condition either partial or complete. 2. Patients maintaining adequate oral hygiene 3. Patients with dimensions of alveolar jaw bone in Occlusso-Gingival position >10mm and Bucco-Lingual position < 6mm  Systemic diseases which are likely to compromise Implant surgery like Diabetes Mellitus Type I, II and Osteoporosis. 2. Patients with oral parafunctional habits like Bruxism. 3. Smokers who smoke more than 10 cigarettes a day. 4. Self-declared pregnancy or intention to become Pregnant. 5. The use of Regenerative procedures in conjunction with Implant placement.Eg Grafts ,Sinus Lift procedures
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 1.0-60.0,  Bone Defect Bone Nonunion the patients with bone defect and bone nonunion caused by tumor or trauma the length of bone defect in long diaphysis is more than 4cm or more than half of the shaft diameter the size of bone defect is more than 5cmx5cm the patients are unable to use autologous bone graft or other treatments the patients request to use the treatment of tissue-engineered bone Supportive family with willingness to participate in completing questionnaires  Patients with serious diseases such as hemorrhagic disorders, infection, tumor, contagion and so on Patients who are pregnant Patients with serious abnormal cardiopulmonary function Patients disagree to use the tissue-engineered bone Patients are older than 60 years Patients who are regarded to be unqualified by investigator
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Soft Tissue Lesions Patient scheduled for clinically indicated conventional Ultrasound examination  Age < 18 years
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Wart Energy Medecine Magnetism Patients with common warts on hands or feet for over at least 3 months are eligible for the study. Patients fulfilling one or more of the following will not be included: lack of informed consent prior to randomization, younger than 18 years or under judicial protection, treated with oral corticotherapy for more than 6 months, immunosuppressed or with history of transplant surgery, undergoing chemotherapy or suspected to have carcinomatous warts, or patients with infected warts, injured warts or already treated within 90 days with chemical processing, medical device, surgery or ever treated with biofield therapy. Subject will be excluded from the study if its warts was treated by other treatment during protocol ulcerated wart cancerous wart
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Myasthenia Gravis Patients between18 to 80 years of age, diagnosed with MG (see below) who have worsening myasthenic symptoms (defined as increasing diplopia, ptosis, dysarthria, dysphagia, difficulty chewing, or limb weakness severe enough to warrant immunoglobulin therapy MG diagnosis will be based upon the clinical evaluation by a neuromuscular expert and meeting any two of the following supportive 1. Abnormal Tensilon test 2. Abnormal repetitive nerve stimulation studies 3. Abnormal single fiber electromyography (EMG) 4. Increased serum acetylcholine receptor or anti-MuSK antibodies 5. Prior response to immunotherapy  Respiratory distress requiring ICU admission or a vital capacity <1 L 2. Severe swallowing difficulties with a high risk of aspiration 3. Change in corticosteroid dosage in the 4 weeks prior to screening 4. Known immunoglobulin A (IgA) deficiency 5. Pregnant or breast feeding women 6. Active renal or hepatic insufficiency, clinically significant cardiac disease 7. Patients with worsening weakness associated with an infectious process 8. Previous lack of responsiveness to IVIG 9. History of previous MG crises
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Idiopathic Parkinson Disease Diagnosis of idiopathic PD with tremor, rigidity or hypokinesia as major symptoms A two to twenty-five-year history of PD with significant medical management or difficulty in medical management A definite response to levodopa compounds with inadequately relieved of symptoms, or severe secondary effects of the drug Good general health A strong will or desire to have the procedure after being fully informed of its experimental nature  History of repeated strokes with stepwise progression of parkinsonian features History of repeated head injury History of definite encephalitis Oculogyric crises (unless drug-induced) Neuroleptic treatment at onset of symptoms Supranuclear gaze palsy Cerebellar signs Babinski sign Presence of cerebral tumor or communicating hydrocephalus on CT scan Sustained remission or negative response to an adequate dose of levodopa
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-30.0,  Chronic Ankle Instability History of at least 1 significant ankle sprain (the most recent injury must have occurred more than 3 months prior to study enrolment) or more episodes of the ankle giving way in the last 6 months A score of ≤24 on the Spanish version of the Cumberland Ankle Instability Tool Age range: 18-30 years  History of previous surgeries to the musculoskeletal structures in either lower extremity History of a fracture in either lower extremity requiring realignment An acute injury to musculoskeletal structures of other joints of the lower extremity in the previous 3 months that impacted joint integrity and function, resulting in at least 1 interrupted day of desired physical activity
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Paget's Disease of Bone for Cases Men and women between the ages of 18-99 years who have evidence of active Paget's disease of bone as clinically and/or radiographically defined by Increased serum alkaline phosphatase or increased serum collagen type 1 c-telopeptide (CTX) or increase in urinary pyridinoline at diagnosis AND history of at least one of the following signs/symptoms: Pagetoid lesions(s) on x-ray/CT/MRI, increased uptake of radioactive substance by bone scan, bone pain, fracture, hearing loss, headache, hypercalcemia, or bony deformity. for controls Men and women between the ages of 18-99 years who match age within 5 years of cases and gender who do NOT have evidence of Paget's disease of bone as defined by No bone pain or bony deformity Normal serum alkaline phosphatase  Osteosarcoma or other blastic bony metastases alone Fibrous dysplasia of bone Hyperostosis frontalis interna All men and women < 18 years or > 99 years Pregnancy (women) determined by self-report Current use of oral contraceptive tablets or Depo-Provera™ (women) Current use of hormone replacement therapy Creatinine clearance < 60 ml/min./1.73 m2 by Cockcroft-Gault based on most recent serum creatinine level (if greater than 1 year since last assessment, will be measured on collected blood sample to verify eligibility) Current smoking or tobacco use Alcohol use greater than 3 units daily
Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Colostomy Ileostomy - Stoma Enterostomy Subject is registered in the Danish Stoma Database Capital Region Is registered as having either ileostomy, jejunostomy, sigmoidostomy, or transversostomy  Patients with urostomy or unknown stoma type